PIXIUM VISION

Their core work

Pixium Vision is a Paris-based medical technology SME specializing in bionic vision systems and retinal implants for patients with severe vision loss. Within the Graphene Flagship, they contribute expertise on biomedical applications of graphene — specifically exploring how 2D materials can improve neural interfaces and optoelectronic implants. Their consistent presence across all four Graphene Flagship phases (Core 1, Core 2, Core 3, and the 2D Experimental Pilot Line) positions them as the biomedical end-user voice within this massive research initiative, translating advanced materials research toward real clinical applications.

What they specialise in

How they've shifted over time

In the early phase (2016–2018), Pixium Vision's involvement centered on broad graphene research with emphasis on biomedical technologies, sensors, photonics, and basic research — exploring where graphene could fit within medical device innovation. By the later phase (2020–2024), their focus narrowed significantly toward FET Flagship priorities, 2D materials, and pilot line development, indicating a move from exploratory research toward manufacturing readiness. This trajectory suggests they have identified specific graphene applications worth scaling and are now working on bringing them closer to production.

Pixium Vision is transitioning from graphene research participation toward pilot-scale production of 2D material components for biomedical devices, making them increasingly relevant for industrialization partnerships.

How they like to work

Pixium Vision operates exclusively as a participant — they have never coordinated an H2020 project, which is typical for a specialized SME contributing domain expertise to large flagship initiatives. With 250 unique consortium partners across 24 countries, they are embedded in one of Europe's largest research networks (the Graphene Flagship consortium regularly exceeds 150 partners). This means working with them gives indirect access to a vast graphene research ecosystem, though their own role is that of a focused contributor rather than a network orchestrator.

Through the Graphene Flagship, Pixium Vision has collaborated with 250 unique partners across 24 European countries — one of the broadest networks possible for an SME, inherited from the flagship's massive consortium structure rather than built independently.

What sets them apart

Pixium Vision occupies a rare niche: they are one of very few medical device SMEs embedded directly in the Graphene Flagship, Europe's largest materials research initiative. While most Flagship partners are universities or materials companies, Pixium brings a concrete clinical application (bionic vision) that grounds the research in patient outcomes. For anyone building a consortium that needs to demonstrate a path from advanced materials to medical devices, Pixium is a credible bridge between lab-scale graphene research and regulated healthcare products.

Highlights from their portfolio

• GrapheneCore1
  Their largest funded project (EUR 210,022), representing their entry into Europe's billion-euro Graphene Flagship as a biomedical application partner.
• 2D-EPL
  The 2D Experimental Pilot Line marks their shift from research to manufacturing readiness, focusing on scalable production of graphene-based components.